The Drug Enforcement Administration (DEA) officially commenced formal administrative proceedings today, June 29, 2026, to evaluate the proposed reclassification of cannabis under the Controlled Substances Act (CSA).
The hearing, held in the North Courtroom at DEA Headquarters in Arlington, Virginia, represents a pivotal moment in federal drug policy. These proceedings will be held under intense scrutiny from industry stakeholders and reform advocates, who argue that the agency’s adherence to procedural rules locked proponents’ views out. We’ll explain why and what’s potentially on the horizon in the federal rescheduling process:
The Shifting Regulatory Framework
Today’s hearing follows a multi-year review sparked by more than 42,000 public comments to the DEA regarding cannabis. That hearing process was delayed and ultimately terminated until Acting Attorney General Todd Blanche issued a new notice of hearing last month. This established a highly compressed schedule to wrap up by July 15, 2026.
The Department of Justice implemented a dual-track framework via a recent final rule, separating medical cannabis from adult-use.
First, the DOJ grantee immediate medical reclassification to FDA-approved drug products containing cannabis and to medicinal state dispensary products subject to a qualifying state-issued license. These products were immediately recategorized from Schedule I to Schedule III.
The administrative trial starting today is tasked with determining whether adult-use (recreational) cannabis and unformulated bulk materials should also be downscheduled to Schedule III through the formal rulemaking process.
Patient and Consumer Implications: A Fractured Outlook
For patients and consumers navigating the nation’s patchwork of state-legal markets, a final transition to Schedule III introduces a complex mix of immediate economic relief and lingering statutory tension.
The immediate inclusion of state-licensed medical cannabis in Schedule III provides a monumental victory for operators and patients. Most notably, MMJ licensees are no longer subject to Internal Revenue Code Section 280E, a decades-old tax restriction that bars standard business deductions for companies trafficking in Schedule I or II substances. The elimination of 280E is expected to heavily reduce operating costs, potentially lowering consumer prices and fueling investment.
Furthermore, removing the Schedule I designation dismantles the federal research gridlock, allowing universities and clinical researchers to study the plant’s safety and efficacy profiles with unprecedented freedom. It may also pave the way for health insurance companies to cover cannabis as medicine for some individuals.
The Recreational Gray Area
If the DEA declines to extend Schedule III status to the recreational sector during this hearing, adult-use cannabis will technically remain a Schedule I substance under federal law.
Additionally, experts warn that Schedule III does not grant a mandate for an open commercial market. Under the Food, Drug, and Cosmetic Act (FDCA), any commercial product containing a controlled substance generally requires explicit FDA approval to enter interstate commerce. Consequently, consumers will not see cannabis transition to traditional pharmacy shelves without extensive further regulatory overhauls.
The Exclusion of Proponents and the Public
The most contentious element of the July 2026 proceedings is the composition of the DEA’s approved witness list, which consists of organizations and state officials who oppose rescheduling. Major advocacy groups, industry trade associations, and consumer coalitions have been barred from formal testimony due to several procedural mechanisms.
To achieve formal participant status as an “interested person” under 21 CFR § 1300.01(b), an entity must demonstrate that they are directly and adversely affected by the proposed rule. The DEA has strictly applied this definition, ruling that generic economic interest, consumer advocacy, or industry representation does not grant a right to participate in this specific administrative courtroom.
The “Sufficient Record” Defense
Administrative justifications for sidelining proponents rely heavily on the existing written record. Because the Department of Health and Human Services (HHS) has issued a scientific recommendation already, and tens of thousands of supportive public comments are already officially documented, further pro-rescheduling testimony wasn’t called for. The hearing’s stated intent is to vet factual challenges raised by opponents.
The Risk of a Lopsided Record
Legal scholars warn that this strategy introduces severe vulnerabilities into the rulemaking process. By conducting an oral hearing that features cross-examination exclusively from prohibitionist groups—such as Smart Approaches to Marijuana and various state attorneys general—the DEA is constructing a heavily lopsided administrative record. If the agency utilizes this testimony to alter its final scheduling determination, the resulting rule will be highly susceptible to future constitutional and procedural lawsuits from the cannabis industry.
Sidelined Advocates
Prior to the finalization of the witness list, a diverse coalition of groups filed formal notices of intention to participate, hoping to secure an active seat at the table.
Organizations including NORML sought to represent the tens of millions of adults who consume cannabis under state laws, arguing that a medical-only framework cannot exist while leaving recreational consumers federally exposed.
At the same time, industry trade groups hoped to present financial data detailing how federal restrictions stifle local small businesses and complicate state-level regulatory enforcement. And hemp industry advocates attempted to participate to clarify the shifting legal boundaries between low-THC hemp derivatives and botanical cannabis ahead of upcoming statutory changes.
So far, it appears these groups will be left out of the hearing and further rulemaking process. The DEA has committed to transparency by promising to publish a finalized and corrected transcript on DEA.gov following the July 15 deadline. But the actual debate shaping the future of federal cannabis policy is being held behind closed doors.
Given how tightly controlled this courtroom proceeding is, the final policy outcome will ultimately depend on whether the DEA’s final determination relies on the lopsided oral arguments presented over the next two weeks, or the vast mountain of scientific and public evidence already resting in the written record.
New Requirements for Medical Cannabis Dispensaries
Under the Department of Justice’s dual-track framework, state-licensed medical cannabis dispensaries are facing an entirely new federal compliance landscape. Because the April 2026 final order immediately shifted state-regulated medical cannabis to Schedule III, these businesses are no longer operating completely outside the federal apparatus.Instead, they are being asked to actively integrate into it.
To legally handle, distribute, or dispense Schedule III cannabis, dispensaries must secure federal registration.The DEA launched a dedicated Medicinal Marijuana Dispensary Registration Portal for this purpose. Operators who filed their applications during an initial now-expired 60-day window qualify for an expedited six-month review process. Dispensaries are required to upload active state medical cannabis licenses, business formation documents, and Federal Employer Identification Numbers (FEIN).
Segregating Medical from Adult-Use Operations
Because recreational cannabis remains a Schedule I controlled substance, operators who have both—this is all licensees in Ohio—are being forced to completely segregate their businesses. This requires strict, traceable separation of inventory, physical facility space, point-of-sale systems, and financial accounting. Only the inventory and revenue directly tied to the medical license qualify for Schedule III status and the subsequent exemption from the Section 280E tax penalty. Registered dispensaries must adapt to standard Schedule III compliance under the Controlled Substances Act. This means moving beyond state “seed-to-sale” tracking systems to implement federal inventory controls, record retention rules, and strict physical security protocols. Dispensaries must conduct an initial on-hand inventory the day they register, followed by a mandatory comprehensive inventory check every two weeks.
A significant point of anxiety for compliance officers and cannabis attorneys is the liability disclosure section within the new DEA registration portal. The application includes mandatory questions regarding past history with controlled substances. Because operators have been selling a federally illegal Schedule I substance for years—even if completely compliant with state law—answering these questions presents unique legal hurdles regarding self-incrimination, requiring operators to carefully coordinate with legal counsel before submitting.
Have Ohio Operators Submitted Yet?
While the DEA does not publish a real-time, public list of pending applicants on its portal, our reporting indicates that Ohio medical cannabis companies been filing for DEA status.
Because the expedited registration window closed just a few days ago (June 26, 2026), Ohio’s major multi-state operators (MSOs) and independent medical licensees faced massive pressure to submit their Form 224-MMP applications on time.
With the expedited deadline now passed, the focus for Ohio’s registered medical companies shifts to preparing their facilities for the federal security audits and strict inventory tracking required of traditional Schedule III handlers.
For the adult-use market, all eyes remain on the outcome of the federal hearings happening now.
To stay up to date on the latest cannabis news, patient and consumer rights in Ohio, Kentucky and beyond:
Subscribe to our Newsletter: Join the MedicateOH & MedicateKY Community
Join our Social Channels: Connect with us on social media to be part of the discussion:Facebook |Instagram |LinkedIn |Reddit
